December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Achieve Life Sciences, Inc. - Common Shares (NQ:ACHV)

4.820 +1.270 (+35.77%)
Streaming Delayed Price Updated: 2:53 PM EDT, Apr 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Achieve Life Sciences, Inc. - Common Shares

< Previous 1 2 Next >
News headline image
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Topline Data Expected in 2Q 2023 
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Life Science Investor Forum Agenda Announced for December 14th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
Achieve Life Sciences Inc. (NASDAQ: ACHV) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Achieve Life Sciences Announces Refresh to Board of Directors
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023 
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Topline Data Expected in 2Q 2023 
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Granting of New Hire Inducement Award
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Granting of New Hire Inducement Award
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences Announces Private Placement of $18.9 Million
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
Phase 2 ORCA-V1 Data Expected in 1H2023 
From Achieve Life Sciences
Via GlobeNewswire
News headline image
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
From Achieve Life Sciences
Via GlobeNewswire
News headline image
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public... 
From MicroCap Rodeo
Via AccessWire
News headline image
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public... 
From MicroCap Rodeo
Via AccessWire
News headline image
Achieve Life Sciences to Participate in Upcoming Investor Conferences
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death
News headline image
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
News headline image
Achieve Life Sciences to Participate in Two Upcoming Investor Conferences
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death
News headline image
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
News headline image
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
News headline image
Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
News headline image
Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and... 
From Achieve Life Sciences, Inc.
Via AccessWire
News headline image
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
News headline image
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE /... 
From Achieve Life Sciences, Inc.
Via AccessWire
Topics Death Intellectual Property
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.